Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma

PURPOSE: To investigate the feasibility of adaptive dosing and the impact of pharmacogenetic variation on 13-cisRA disposition in high-risk neuroblastoma patients. EXPERIMENTAL DESIGN: 13cisRA (160mg/m(2) or 5.33mg/kg/day) was administered to 103 patients ≤21 years and plasma concentrations of 13-ci...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Veal, Gareth J., Errington, Julie, Rowbotham, Sophie E., Illingworth, Nicola A., Malik, Ghada, Cole, Michael, Daly, Ann K., Pearson, Andrew D.J., Boddy, Alan V.
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548903/
https://ncbi.nlm.nih.gov/pubmed/23087409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2225
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires